Drug Trial Radar · NCT07301255
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jan 9, 2026
Primary completion
Dec 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Enveda TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
Conditions
- Asthma
Interventions
ENV-294Drug
ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks.
PlaceboDrug
Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse EventsTime frame: From first dose through approximately 16 weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Enveda Investigative Site
Birmingham, Alabama · Recruiting
Enveda Investigative Site
Los Angeles, California · Recruiting
Enveda Investigative Site
San Jose, California · Recruiting
Enveda Investigative Site
West Hills, California · Recruiting
Enveda Investigative Site
Colorado Springs, Colorado · Recruiting
Enveda Investigative Site
Hialeah, Florida · Recruiting
Enveda Investigative Site
Miami, Florida · Recruiting
Enveda Investigative Site
Albany, Georgia · Recruiting
Enveda Investigative Site
Maryville, Illinois · Recruiting
Enveda Investigative Site
Kansas City, Kansas · Recruiting
Enveda Investigative Site
Owensboro, Kentucky · Recruiting
Enveda Investigative Site
Boston, Massachusetts · Recruiting
Enveda Investigative Site
Southfield, Michigan · Recruiting
Enveda Investigative Site
St Louis, Missouri · Recruiting
Enveda Investigative Site
The Bronx, New York · Recruiting
Enveda Investigative Site
Clackamas, Oregon · Recruiting
Enveda Investigative Site
Medford, Oregon · Recruiting
Enveda Investigative Site
North Charleston, South Carolina · Recruiting
Enveda Investigative Site
McKinney, Texas · Recruiting
Enveda Investigative Site
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.